Department of Respiratory Medicine, Sasebo City General Hospital, Nagasaki, Japan.
Department of Pathology, Sasebo City General Hospital, Nagasaki, Japan.
Thorac Cancer. 2018 Jan;9(1):193-196. doi: 10.1111/1759-7714.12557. Epub 2017 Nov 13.
Pulmonary pleomorphic carcinoma has been shown to respond remarkably to PD-1 inhibitors; however, the biomarkers for this therapy have not been fully proven. We report a case of pulmonary pleomorphic carcinoma with overexpressed PD-L1, in which a complete response to nivolumab was sustained for >14 months. Immunohistochemical analysis revealed few PD-1 immune cells and regulatory T cells in the tumor, in addition to predominant infiltration of CD8 cells and macrophages. Our findings suggest that the presence of a small number of PD-1 immune cells and regulatory T cells should be investigated as candidate therapeutic biomarkers.
肺多形性癌对 PD-1 抑制剂有显著反应；然而，这种治疗的生物标志物尚未得到充分证实。我们报告了一例 PD-L1 过表达的肺多形性癌，其对nivolumab 的完全缓解持续了>14 个月。免疫组织化学分析显示，肿瘤中 PD-1 免疫细胞和调节性 T 细胞很少，除了 CD8 细胞和巨噬细胞的主要浸润。我们的研究结果表明，应研究少量 PD-1 免疫细胞和调节性 T 细胞的存在作为候选治疗生物标志物。
